MLR Maelor

RNS Number:6049L
Maelor PLC
28 April 2005

28th April 2005

Maelor plc Appoints Geoffrey McMillan as Non-Executive Director

Maelor plc, the specialist healthcare products company, today announced the
appointment of Geoffrey McMillan as a Non-Executive Director with effect from
1st May, 2005.

Mr McMillan is currently the Chief Executive Officer of BioFocus plc, and has
led the transition of that company from a founder-based service company to an
integrated and profitable provider of drug discovery products, services and
programmes.  He had previously held Board positions at Roche, Xenova and Elan.

Alastair Macpherson, Chairman of Maelor plc, said: "Geoff's exceptional
experience within the pharmaceutical and biotechnology sectors, particularly in
product licensing and mergers and acquisitions, will provide us with a valuable
insight in key strategic areas for Maelor.  He strengthens the Board at an
important point in Maelor's development when we are reaping the rewards of our
investment in R+D, and looking forward to our current portfolio of products
delivering profitability."

Directorship Details: Henry Geoffrey McMillan, aged 48, currently holds and has
held directorships, during the five years preceding the date of this
announcement as follows:

Current                    Past

BioFocus plc               Elan Pharma International Ltd (Ireland)
                           Elan Pharma (Ireland) Ltd
                           Elan Pharma GmbH (Germany)
                           Elan Pharma AB (Sweden)
                           Elan Pharma Italy
                           Elan Pharma France
                           Elan Pharmaceutical Corporation (Philippines)
                           Vita Elan (Spain)
                           Manga Holdings (Spain)

There are no further disclosures to be made in accordance with Schedule 2 (f) of
the AIM Rules.

-ends-

For further information:

Maelor plc         Stephen Appelbee, Chief Executive Officer  Tel: 01978 810 153
Financial Dynamics Ben Atwell / Lucy Briggs                   Tel: 0207 831 3113

Notes to editors:

Maelor plc

Maelor is an AiM-listed specialist healthcare products company. The company has
several products on the market including OptiFlo(R), ContiSol and Volplex.

OptiFlo, a urethral catheter maintenance range, launched in the UK in June 1999
and distributed through Bard Limited, has gained a 45% share of the UK community
prescription market (source: IMS, February 2005).

ContiSol, Maelor's own-brand urethral catheter maintenance range, has already
been launched in Spain (by CAIR Espana SL) and in Greece (by M. S. Jacovides
SA).  The product has also gained approval in Canada where the recently
appointed distributor American Australian Medical, Inc., will be launching
shortly.

Volplex, the company's blood plasma volume substitute, is used for patients
suffering from the effects of trauma, surgery or certain medical conditions
which result in hypovolaemia (lower than normal blood volume). It is distributed
in the UK by Cambridge Laboratories Ltd, and in Argentina by Ahimsa SA.

Maelor has various products under development including micelle propofol, a
reformulation of the world's biggest-selling general anaesthetic.

Volplex(R) and ContiSol(TM) are trademarks of Maelor Pharmaceuticals Limited

OptiFlo(R) is a trademark of Bard Limited


                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

BOADGGZDDNZGKZM

Maelor (LSE:MLR)
Historical Stock Chart
From Nov 2024 to Dec 2024

Maelor (LSE:MLR)
Historical Stock Chart
From Dec 2023 to Dec 2024